Radiopharm Theranostics Announces Completion Of EOP2 Meeting With FDA Regarding RAD101, Investigational Radiopharmaceutical Imaging Agent For Detection Of Brain Metastases

Radiopharm Theranostics Limited has successfully completed an End-of-Phase 2 meeting with the FDA regarding RAD101, an investigational radiopharmaceutical imaging agent for detecting brain metastases. The company is currently engaged in Phase 3 readiness activities and expects to receive official FDA meeting minutes within the next 30 days, which will outline the Agency's feedback on the pivotal clinical development plan. RAD101 has shown a 93% concordance with MRI in previous Phase 2b trials, meeting its primary endpoint.